Skip to main content

NEW YORK (TheStreet) -- Shares of Actavis (ACT) - Get Enact Holdings Inc Report are slightly higher on Tuesday, as analysts at Goldman Sachs place the stock on its conviction buy list and assigned a price target of $365. 

If the analysts are correct and the company does earn $24 per share in 2017, the stock has much more upside, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment. 

The stock has also traded well since its secondary offering and the company's acquisition of Allergan (AGN) - Get Allergan plc Report could be highly accretive, he added. 

"If they can monetize Allergan the way I think it can," the stock is going much higher, Cramer said. 

Actavis CEO Brenton Saunders is "extraordinary," Cramer said, adding that the company will continue to benefit from the many different uses of Botox

TheStreet Recommends

Actavis ACT data by YCharts

Image placeholder title

Cramer turned his attention to MGM Resort International (MGM) - Get MGM Resorts International Report, as shares soared 9% after Land and Buildings, an activist investment firm, said there's 70% upside in the stock citing "substantial real estate value." The firm suggested MGM Resort should convert to a REIT. 

Many of the casino stocks have been trading lower due to having exposure to Macau, Cramer said. However, MGM Resort has the least exposure to the region compared with its peers, he added. 

"So I don't think this is a bad call at all," he concluded. Cramer did say he would avoid stocks that have high exposure to Macau, such as Wynn Resorts (WYNN) - Get Wynn Resorts, Limited Report

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.